Prognostic biomarkers
tumor
TUMOR
In post-hoc analyses, the prognostic value of genomic alterations and altered signaling pathways was assessed among the 56 patients with contributive DNAseq on baseline tumor (Supplementary Table We next focused on the top 10% of patients with the highest tumor mutational burden (TMB) scores corresponding to a TMB > 15.5 mut/Mb. There was no difference in OS between patients with high TMB (> 15.5 mut/Mb) and low TMB (≤ 15.5 mut/Mb), with an HR of 0.9 (95% CI, 0.22–4.0; Supplementary Fig. 